Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.

23 Sep, 2022 | 13:07h | UTC

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations – The BMJ

 

Commentary on Twitter

 


M-A of the association between new hypoglycemic agents and digestive diseases.

22 Sep, 2022 | 13:16h | UTC

Meta-analysis of the association between new hypoglycemic agents and digestive diseases – Medicine

Commentary: Spotlight on digestive risks of newer diabetes drugs – ACP Gastroenterology

 


A quality improvement study showed that a clinic–based aspirin deimplementation intervention can reduce inappropriate aspirin prescribing and bleeding in patients receiving warfarin for anticoagulation.

22 Sep, 2022 | 13:14h | UTC

Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation – JAMA Network Open

News Release: Stopping aspirin when on a blood thinner lowers risk of bleeding, study finds – Michigan Medicine

 

Commentary on Twitter

 


Observational study suggests an increased risk of adverse events with the use of perioperative Gabapentin for pain management.

21 Sep, 2022 | 13:20h | UTC

Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery – JAMA Internal Medicine (free for a limited period)

Invited Commentary: Perioperative Gabapentin Use in Older Adults: Revisiting Multimodal Pain Management – JAMA Internal Medicine (free for a limited period)

 

Commentary on Twitter

 


Review | Obesity and contraceptive use: impact on cardiovascular risk.

16 Sep, 2022 | 12:53h | UTC

Obesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure

News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology

 


Study | Vitamin D3 and omega-3 fatty acids not helpful in reducing the risk of frailty.

14 Sep, 2022 | 13:20h | UTC

News Release: Vitamin D3 and omega-3 fatty acids not helpful in reducing risk of frailty – Brigham and Women’s Hospital

Original Study: Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial – JAMA Network Open

Invited Commentary: There Is No Magic Pill to Prevent Frailty—You Still Have to Eat Your Vegetables – JAMA Network Open

 

Commentary on Twitter

 


Network M-A | Comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of LDL cholesterol.

11 Sep, 2022 | 22:38h | UTC

Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol – Journal of the American Heart Association

 


Nonadherence was revealed through measurements of serum concentrations of antihypertensive drugs in one-third of patients with resistant hypertension previously evaluated as adherent.

11 Sep, 2022 | 22:35h | UTC

Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy – Journal of the American Heart Association

 


Guideline Summary | Management of patients with suspected or confirmed antibiotic allergy.

8 Sep, 2022 | 14:42h | UTC

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

Related:

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 


Perspective | Psychedelic drugs take on depression.

8 Sep, 2022 | 14:32h | UTC

Psychedelic drugs take on depression – Nature

 


Systematic Review | Probiotics for preventing acute upper respiratory tract infections.

6 Sep, 2022 | 14:40h | UTC

Probiotics for preventing acute upper respiratory tract infections – Cochrane Library

 

Commentary on Twitter

 


Study raises concerns about the effectiveness of the monkeypox vaccine.

6 Sep, 2022 | 14:39h | UTC

Study raises concerns about the effectiveness of the monkeypox vaccine – STAT

Original Study (Preprint): Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals – medRxiv

 


Systematic Review | Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

6 Sep, 2022 | 14:31h | UTC

Opioid agonist treatment for people who are dependent on pharmaceutical opioids – Cochrane Library

Summary: Opioid maintenance medicines for the treatment of dependence on opioid pain medicines – Cochrane Library

 


Review | Cardiovascular complications of immune checkpoint inhibitors for cancer.

6 Sep, 2022 | 14:20h | UTC

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Related:

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 

Commentary on Twitter

 


Consensus Statement | Preoperative management of cardiovascular medications.

5 Sep, 2022 | 14:42h | UTC

Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Related:

Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Neurologic Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Psychiatric Diseases: Society for Perioperative Assessment and Quality Improvement Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Opioid and Nonopioid Analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Surgical Patients Using Dietary Supplements – Mayo Clinic Proceedings

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Preoperative Cardiac Risk Assessment – Mayo Clinic Proceedings

Preoperative Evaluation Before Noncardiac Surgery – Mayo Clinic Proceedings

Perioperative Cardiac Risk Reduction in Noncardiac Surgery – Mayo Clinic Proceedings

Examining Risk: A Systematic Review of Perioperative Cardiac Risk Prediction Indices – Mayo Clinic Proceedings

Perioperative Venous Thromboembolism Prophylaxis – Mayo Clinic Proceedings

 


FDA authorizes updated COVID boosters from Moderna and Pfizer.

5 Sep, 2022 | 14:36h | UTC

FDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP

FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration

 


Review | The prevention and treatment of nausea and vomiting during tumor therapy.

5 Sep, 2022 | 14:23h | UTC

The Prevention and Treatment of Nausea and Vomiting During Tumor Therapy – Deutsches Ärzteblatt International

Related:

SEOM clinical guideline emesis (2021) – Clinical and Translational Oncology

M-A: Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy.

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)

 


2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.

2 Sep, 2022 | 13:17h | UTC

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

News Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology

Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD

 

Commentary on Twitter

 


Review | Covid-19 vaccines — immunity, variants, boosters.

1 Sep, 2022 | 11:57h | UTC

Covid-19 Vaccines — Immunity, Variants, Boosters – New England Journal of Medicine

 


Study Commentary | Zinc for the prevention or treatment of respiratory tract infections: a new systematic review.

1 Sep, 2022 | 11:46h | UTC

Zinc for the prevention or treatment of respiratory tract infections: A new systematic review – Science-Based Medicine

Original Study: M-A: Zinc might help to stave off respiratory infection symptoms and cut illness duration – “But quality of evidence variable, and no clarity on optimal formulation or dose”.

 


Study shows dentists should give antibiotics to high-risk patients to help prevent infectious endocarditis.

1 Sep, 2022 | 11:43h | UTC

News Release: Dentists should give antibiotics to high-risk patients to help prevent life-threatening heart infection – The University of Sheffield

Original Study: Antibiotic Prophylaxis Against Infective Endocarditis Before Invasive Dental Procedures – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentary: UK dentists should give antibiotics to patients at risk of heart infection – study – The Guardian

 


Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.

31 Aug, 2022 | 11:51h | UTC

Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified – Blood Pressure

 


#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

 


#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.

30 Aug, 2022 | 12:14h | UTC

News Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology

Original Study: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER – Nature Medicine

Related:

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

 


Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.

30 Aug, 2022 | 11:59h | UTC

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)

Related: Meta-analysis of randomized trials: GLP1 receptor agonists increase the risk of gallbladder and biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

 


Stay Updated in Your Specialty

No spam, just news.